Get the Stockscreener App
38.34
0.76%
0.29
Cytokinetics Inc stock is traded at $38.34, with a volume of 1.55M.
It is up +0.76% in the last 24 hours and up +1.70% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$38.05
Open:
$38.11
24h Volume:
1.55M
Relative Volume:
1.06
Market Cap:
$4.59B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-7.289
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-0.85%
1M Performance:
+1.70%
6M Performance:
-23.72%
1Y Performance:
-31.84%
1-Day Range:
$37.68
$39.14
1-Week Range:
$36.77
$39.45
52-Week Range:
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
38.34 | 4.66B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics: Specialty Franchise With Aficamten And Ulacamten (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics Names Jim Daly to Board of Directors - The Globe and Mail
Cytokinetics appoints James Daly to board of directors - Investing.com
Cytokinetics Appoints James M. Daly to Board of Directors - Quiver Quantitative
Cytokinetics Appoints James Daly to Board with Commercialization Expertise. - AInvest
Former Incyte & Amgen Commercial Leader Jim Daly Joins Cytokinetics Board as Company Preps Commercial Push - Stock Titan
Cytokinetics Inc Announces Stock Options and RSUs for New Employees Amid Ongoing Cardiovascular Advancements - AInvest
Cytokinetics EVP Malik sells $76k in shares - Investing.com
Cytokinetics EVP Malik sells $76k in shares By Investing.com - Investing.com UK
Cytokinetics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
105,169 Stock Options at $38.67: Cytokinetics Issues Major Employee Inducement Grants - Stock Titan
Cytokinetics Incorporated Inches Above Key Support — Safe to Hold2025 Volatility Report & High Return Trade Guides - 선데이타임즈
Will Cytokinetics Incorporated Recover After Recent DeclineJuly 2025 Analyst Calls & AI Driven Stock Movement Reports - newsimpact.co.kr
Is Cytokinetics Incorporated’s ROE strong enoughJuly 2025 Pullbacks & Free High Return Stock Watch Alerts - thegnnews.com
Cytokinetics (CYTK) Receives Buy Rating from Mizuho Securities with $84 Price Target - AInvest
Cytokinetics CEO Cashes In on Stock Sale - TipRanks
Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings - MSN
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape By Investing.com - Investing.com Canada
Cytokinetics, Incorporated Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsCYTK - ACCESS Newswire
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Traders Expect Breakout From Cytokinetics Incorporated This WeekReal Trader Watchlist of Hot Stocks Released - beatles.ru
Cytokinetics: Promising Outlook with Aficamten’s Regulatory Progress and Strong Financial Health - TipRanks
Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (OMDA), Gilead Sciences (GILD) and Cytokinetics (CYTK) - The Globe and Mail
Is Cytokinetics Incorporated stock entering bullish territoryPrice Movement and Market Sentiment Analysis - Newser
Using Ichimoku Cloud for Cytokinetics Incorporated technicalsSafe Momentum Strategy With Trend Analysis - Newser
Citigroup Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - Defense World
Cytokinetics (NASDAQ:CYTK) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Cytokinetics and the Imminent Commercialization of Aficamten: A High-Conviction Buy Before the December 2025 FDA Decision - AInvest
Cytokinetics and the Aficamten Opportunity: Navigating FDA Delays, Strong Analyst Consensus, and High GF Value for a High-Probability Breakout in 2026 - AInvest
Cytokinetics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Pattern recognition hints at Cytokinetics Incorporated upsideTechnical Safety Zone Pattern Recognition - Newser
What candlestick patterns are forming on Cytokinetics IncorporatedFree High Yield Stock Screening Results - Newser
What indicators show strength in Cytokinetics IncorporatedFree Pattern Breakout Entry Stock Forecast - Newser
Cytokinetics 2025 Q2 Earnings Narrowed Losses Amid Revenue Surge - AInvest
Cytokinetics: Citigroup maintains Buy rating, lowers PT to $77 from $80. - AInvest
Cytokinetics shares rise 3.20% after-hours following Q2 2025 earnings call. - AInvest
Cytokinetics, Incorporated shares fall 1.56% intraday after reporting earnings and regulatory updates. - AInvest
CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $53 to $120 - 富途牛牛
Cytokinetics rises as investors await US approval for heart drug - TradingView
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat - Investing.com
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat By Investing.com - Investing.com South Africa
Navigating Financial Challenges Amid Promising Clinical Developments: Cytokinetics Inc. (CYTK) Q2 2025 Earnings Call Highlights - AInvest
Cytokinetics Q2 Loss Narrows, Revenue Rises - MarketScreener
Cytokinetics Q2 2025 Earnings Call Transcript - MarketBeat
Cytokinetics Reports Q2 2025 Financial Results and Updates - TipRanks
Cytokinetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cytokinetics shares rise on strong Q2 results By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Aug 19 '25 |
Sale |
38.31 |
2,000 |
76,620 |
140,610 |
| Blum Robert I | President & CEO |
Aug 15 '25 |
Sale |
38.42 |
5,000 |
192,100 |
383,108 |
| Malik Fady Ibraham | EVP Research & Development |
Aug 05 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,610 |
| Malik Fady Ibraham | EVP Research & Development |
Aug 05 '25 |
Sale |
36.34 |
2,000 |
72,680 |
140,610 |
| Blum Robert I | President & CEO |
Jul 29 '25 |
Sale |
36.45 |
5,000 |
182,250 |
388,108 |
| Malik Fady Ibraham | EVP Research & Development |
Jul 22 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,610 |
| Malik Fady Ibraham | EVP Research & Development |
Jul 22 '25 |
Sale |
37.47 |
2,000 |
74,940 |
140,610 |
| Blum Robert I | President & CEO |
Jul 14 '25 |
Sale |
38.15 |
5,000 |
190,750 |
393,108 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):